PUBLIC COMPANY
save$ABOSAcumen Pharmaceuticals, Inc.
$ABOSNewton, MA, USupdated 21d ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
- phase1A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants
- phase1A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD
Insider activity
source: SEC Form 4open-market buys + sells
routine RSU / option mechanics (5)
- Mar 16, 26grantRA CAPITAL MANAGEMENT, L.P. · 6,060,606 sh
- Mar 6, 26option exerciseMeisner Derek M · Chief Legal Officer & Corp Sec2,090 sh
- Mar 6, 26option exerciseMeisner Derek M · Chief Legal Officer & Corp Sec2,090 sh
- Feb 27, 26option exerciseMeisner Derek M · Chief Legal Officer & Corp Sec9,406 sh
- Feb 27, 26option exerciseMeisner Derek M · Chief Legal Officer & Corp Sec9,406 sh
🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
last refreshed 18m ago
Found something off?
comments(0)
5-min edit window · permanent after that